{"prompt": "['46', 'MC1488 WEE1', 'MCCC', 'Investigations', 'Neutrophil count decreased', 'X', 'X', 'Platelet count decreased', 'X', 'X', 'AST Increased', 'X', 'X', 'ALT Increased', 'X', 'X', '10.61 Submit via appropriate MCCC Case Report Forms (i.e., paper or electronic, as', 'applicable) the following AEs experienced by a patient and not specified', 'in Section 10.6:', '10.611 Grade 2 AEs deemed possibly, probably, or definitely related to the study', 'treatment or procedure.', '10.612 Grade 3 and 4 AEs regardless of attribution to the study treatment or', 'procedure.', '10.613 Grade 5 AEs (Deaths)', '10.6131', \"Any death within 30 days of the patient's last study\", 'treatment or procedure regardless of attribution to the study', 'treatment or procedure.', '10.6132', \"Any death more than 30 days after the patient's last study\", 'treatment or procedure that is felt to be at least possibly', 'treatment related must also be submitted as a Grade 5 AE,', 'with a CTCAE type and attribution assigned.', '10.62 Refer to the instructions in the Forms Packet (or electronic data entry screens, as', 'applicable) regarding the submission of late occurring AEs following completion of the Active', 'Monitoring Phase (i.e., compliance with Test Schedule in Section 4.0).', '11.0', 'Treatment Evaluation Guideline', 'Note:', 'Novel combinations in AML/MDS may be expected to result in different response', 'kinetics than \"conventional\" cytotoxic regimens. Thus initial blast % increase may not', 'accurately reflect later stage responses. AraC, if given SC may lead to differentiation.', 'There will be no pre-specified number of cycles and patients can remain on study as long', 'as they tolerate the combination and/or derive clinical benefit.', '11.1', 'AML response criteria', '11.11', 'Complete hematologic response (CR)', 'Less than 5% blasts in a non-hypocellular marrow with a granulocyte count >', '1.0, and a platelets count of > 100 with complete resolution of', 'extramedullary disease and absence of peripheral blood blasts.', 'CR incomplete (CRi) is called if patient meets all CR criteria except for residual', 'neutropenia (ANC<1 x109/L) or thrombocytopenia (platelets<100 x109/L', '11.111 Complete cytogenetic remission (CCyR)']['47', 'MC1488 WEE1', 'MCCC', 'The absence of chromosome abnormalities (if present at diagnosis) on', 'conventional cytogenetic study using G-banding (at least 10 metaphases', 'present).', '11.12', 'Morphologic leukemia-free state (MLFS):', 'If bone marrow blasts <5%, absence of Auer rods blasts, absence of', 'extramedullary disease without hematological recovery.', '11.13', 'Partial remission (PR)', 'The presence of trilineage hematopoiesis in the bone marrow with recovery of', 'ANC and platelet count to above levels, but with 5-25% bone marrow blasts and', '>50% decrease in bone marrow blast percentage from baseline.', '11.14', 'No response (NR)', 'Failure to achieve a PR, MLFS, CRi, or CR.', '11.15', 'Relapse:', 'Disease recurrence after achieving CR. Disease recurrence is defined by blast', '>5% in the bone marrow, or recurrence of peripheral blood blasts or', 'extramedullary involvement.', '11.2', 'MDS and CMML response criteria', 'Category', 'Hematologic Response', 'Response Criteria (responses must last at least 4 weeks)', 'Complete remission (CR)', 'Bone marrow: 5% myeloblasts with maturation of all cell lines.', 'If present, persistent dysplasia will be noted (dysplastic changes', 'should consider the normal range of dysplastic changes.)', 'Peripheral blood:', 'Hemoglobin (Hgb) >11 g/dL (untransfused, patient not on', 'erythropoietin)', 'Neutrophils >1.0 X 109/L (not on myeloid growth factor)', 'Platelets >100 X 109/L (not on a thrombopoietic agent)', 'Blasts 0%;', 'Partial remission (PR)', 'All CR criteria (if abnormal prior to treatment), except:', 'Bone marrow blasts decreased by >50% compared with', 'pretreatment but still >5%.', 'Cellularity and morphology not relevant.', 'Marrow CR', 'Bone marrow: V 5% myeloblasts and decrease by >50% over', 'pretreatment if > 10% at baseline', 'Peripheral blood: if hematologic improvement (HI) responses,', 'they will be noted in addition to the marrow CR', 'Stable disease (SD)', 'Failure to achieve at least PR, but no evidence of progression for', '>8 weeks.', 'Failure', 'Death during treatment or disease progression characterized by', 'worsening of cytopenias, increase in percentage of bone marrow', 'blasts, or progression to an MDS FAB subtype more advanced', 'than pretreatment after 6 months/cycles of therapy']\n\n###\n\n", "completion": "END"}